Evidence map›Paper›PMID 41256323›Full record

ArticleFrontiers in oncology2025

Definitive radiotherapy for local and metastatic lesions in prostate cancer patients with oligometastases.

Bichun Xu, Xianzhi Zhao, Yiyin Liang, Weiwei Zhang, Liang Chen, Yusheng Ye, Jie He, Jiaojiao Tong, Yangyang Gong, Judong Luo and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bichun Xu *Department of Radiation Oncology, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
Xianzhi Zhao *Department of Radiation Oncology, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
Yiyin LiangDepartment of Radiation Oncology, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
Weiwei ZhangDepartment of Radiation Oncology, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
Liang ChenDepartment of Radiation Oncology, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
Yusheng YeDepartment of Radiation Oncology, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
Jie HeDepartment of Radiation Oncology, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
Jiaojiao TongDepartment of Radiation Oncology, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
Yangyang GongDepartment of Radiation Oncology, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
Judong LuoDepartment of Radiotherapy, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Huojun ZhangDepartment of Radiation Oncology, The First Affiliated Hospital of Naval Medical University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Few studies explore the role of definitive radiotherapy for prostate and all metastases in the treatment of low-burden oligometastatic prostate cancer (omPCa). This study aimed to investigate the potential survival benefit of this approach. Moreover, it is the first study to report the outcomes of definitive radiotherapy for local and distant metastatic lesions in patients with omPCa from China. Methods: A retrospective analysis was conducted on patients with omPCa who received definitive radiotherapy for the primary site and metastatic lesions between July 2012 and June 2022. The inclusion criteria mandated fewer than 5 oligometastases, excluding regional lymph nodes by imaging examinations with no prior radiotherapy or radical prostatectomy for omPCa. Overall survival (OS) was the primary endpoint, and biochemical progression-free survival (bPFS) and radiological progression-free survival (rPFS) were the secondary endpoint. The Kaplan-Meier method was used to estimate survival rates. Univariate and multivariate analyses were conducted using Cox proportional hazards regression models. Results: A total of 33 patients, including 31 Conclusion: Definitive radiotherapy for local/metastatic lesions demonstrates promising survival with manageable toxicity in omPCa.

Indexed as

definitiveoligometastasesoverall survivalprostate cancerradiotherapy

Identifiers

PMID41256323
PMCPMC12620242

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.